Research Progress of Chinese Medicine Monomers in Treatment of Cholangiocarcinoma  

作　　者：WANG Xiang WANG Xiao-qing LUO Kai BAI He QU Jia-lin ZHANG Gui-xin 

机构地区：[1]Department of General Surgery,the Second Hospital of Dalian Medical University,Dalian,Liaoning Province(116027),China [2]Clinical Laboratory of Integrative Medicine,First Affiliated Hospital of Dalian Medical University,Dalian,Liaoning Province(116021),China [3]Hepatobiliary Surgery Department,Shandong Provincial Third Hospittal,Shandong University,Jinan(250031),China [4]Institute(College)of Integrative Medicine,Dalian Medical University,Dalian,Liaoning Province(116044),China

出　　处：《Chinese Journal of Integrative Medicine》2025年第2期170-182,共13页中国结合医学杂志(英文版)

基　　金：Supported by the Grants from the National Natural Science Foundation of China(No.82174136);Dalian Medical University Intensified Program of Wellness Interdisciplinary Research Cooperation Project Team Funding(No.JCHZ2023004)。

摘　　要：Cholangiocarcinoma(CCA)is a malignant tumor originating from cholangiocytes.However,it remains unclear about the pathogenesis of this carcinoma,which may be related to multiple factors.Currently,CCA is mainly treated by surgery,chemotherapy,and radiotherapy.Among them,surgery is the only potentially curative option for CCA.Nevertheless,the high malignancy and asymptomatic nature of CCA may lead to poor treatment outcomes.It has been demonstrated that Chinese medicine(CM)plays a significant role in various antitumor applications.Meanwhile,CM exhibits fewer side effects and high availability.Moreover,the in vitro application of CM monomers has been explored in many domestic and foreign studies.This article mainly reviews the signaling pathways and molecular mechanisms of CM monomers in the treatment of CCA in recent years.These findings are expected to provide new insights into the treatment of CCA.

关 键 词：CHOLANGIOCARCINOMA Chinese medicine MONOMERS ANTITUMOR signaling pathways molecular mechanisms REVIEW 

分 类 号：R73[医药卫生—肿瘤]